Targeting anti-inflammatory ANXA1 and its receptors have achieved satisfyingly protective effects in many inflammation diseases, including sepsis-induced acute kidney injury (SI-AKI) and endotoxin-induced cerebral inflammation (39, 40). This evidence concerns the gene ANXA1 and Sepsis.